New and experimental skin-directed therapies for cutaneous lymphomas

Arpad Farkas, L. Kemény, Lars E. French, Reinhard Dummer

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Primary cutaneous lymphomas (CLs) originate in the skin and should be differentiated from secondary skin infiltrates, which are manifestations of lymphomas of nodal or extranodal origin. These rare diseases include various lymphoproliferative disorders: cutaneous T-cell lymphomas, cutaneous B-cell lymphomas and some rare subtypes. As definitive cure is often not possible, it is important to control the disease and alleviate symptoms. Patients with early-stage disease limited to the skin usually require skin-directed therapies using topical agents including corticosteroids, chemotherapeutic drugs, bexarotene gel, electron beam therapy and phototherapy. Each of these are effective; however, all have some disadvantages and are associated with significant adverse events. In the field of skin-directed therapies there are interesting developments using antineoplastic compounds, the retinoid tazarotene, imiquimod, gene therapy products (adenovirus vector expressing γ-interferon), the monoclonal anti-CD20 antibody rituximab, photodynamic therapy and 308-nm excimer laser to mention a few. This review highlights some of the promising new and experimental local therapies for primary CLs and focuses on their efficacy and side effects.

Original languageEnglish
Pages (from-to)322-334
Number of pages13
JournalSkin Pharmacology and Physiology
Volume22
Issue number6
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Lymphoma
Skin
Therapeutics
imiquimod
Cutaneous T-Cell Lymphoma
Excimer Lasers
Investigational Therapies
Phototherapy
Lymphoproliferative Disorders
Retinoids
Photochemotherapy
B-Cell Lymphoma
Rare Diseases
Adenoviridae
Genetic Therapy
Antineoplastic Agents
Interferons
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Gels

Keywords

  • 308-nm excimer laser
  • Cutaneous lymphoma
  • Hexadecylphosphocholine
  • Imiquimod
  • Methotrexate
  • Photodynamic therapy
  • Rituximab
  • Skin-directed therapy
  • Tazarotene
  • TG-1042

ASJC Scopus subject areas

  • Pharmacology
  • Physiology
  • Dermatology

Cite this

New and experimental skin-directed therapies for cutaneous lymphomas. / Farkas, Arpad; Kemény, L.; French, Lars E.; Dummer, Reinhard.

In: Skin Pharmacology and Physiology, Vol. 22, No. 6, 11.2009, p. 322-334.

Research output: Contribution to journalArticle

Farkas, Arpad ; Kemény, L. ; French, Lars E. ; Dummer, Reinhard. / New and experimental skin-directed therapies for cutaneous lymphomas. In: Skin Pharmacology and Physiology. 2009 ; Vol. 22, No. 6. pp. 322-334.
@article{cc9e0ad9a26e479dbcbd0cc570b5bf31,
title = "New and experimental skin-directed therapies for cutaneous lymphomas",
abstract = "Primary cutaneous lymphomas (CLs) originate in the skin and should be differentiated from secondary skin infiltrates, which are manifestations of lymphomas of nodal or extranodal origin. These rare diseases include various lymphoproliferative disorders: cutaneous T-cell lymphomas, cutaneous B-cell lymphomas and some rare subtypes. As definitive cure is often not possible, it is important to control the disease and alleviate symptoms. Patients with early-stage disease limited to the skin usually require skin-directed therapies using topical agents including corticosteroids, chemotherapeutic drugs, bexarotene gel, electron beam therapy and phototherapy. Each of these are effective; however, all have some disadvantages and are associated with significant adverse events. In the field of skin-directed therapies there are interesting developments using antineoplastic compounds, the retinoid tazarotene, imiquimod, gene therapy products (adenovirus vector expressing γ-interferon), the monoclonal anti-CD20 antibody rituximab, photodynamic therapy and 308-nm excimer laser to mention a few. This review highlights some of the promising new and experimental local therapies for primary CLs and focuses on their efficacy and side effects.",
keywords = "308-nm excimer laser, Cutaneous lymphoma, Hexadecylphosphocholine, Imiquimod, Methotrexate, Photodynamic therapy, Rituximab, Skin-directed therapy, Tazarotene, TG-1042",
author = "Arpad Farkas and L. Kem{\'e}ny and French, {Lars E.} and Reinhard Dummer",
year = "2009",
month = "11",
doi = "10.1159/000241302",
language = "English",
volume = "22",
pages = "322--334",
journal = "Skin Pharmacology and Physiology",
issn = "1660-5527",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - New and experimental skin-directed therapies for cutaneous lymphomas

AU - Farkas, Arpad

AU - Kemény, L.

AU - French, Lars E.

AU - Dummer, Reinhard

PY - 2009/11

Y1 - 2009/11

N2 - Primary cutaneous lymphomas (CLs) originate in the skin and should be differentiated from secondary skin infiltrates, which are manifestations of lymphomas of nodal or extranodal origin. These rare diseases include various lymphoproliferative disorders: cutaneous T-cell lymphomas, cutaneous B-cell lymphomas and some rare subtypes. As definitive cure is often not possible, it is important to control the disease and alleviate symptoms. Patients with early-stage disease limited to the skin usually require skin-directed therapies using topical agents including corticosteroids, chemotherapeutic drugs, bexarotene gel, electron beam therapy and phototherapy. Each of these are effective; however, all have some disadvantages and are associated with significant adverse events. In the field of skin-directed therapies there are interesting developments using antineoplastic compounds, the retinoid tazarotene, imiquimod, gene therapy products (adenovirus vector expressing γ-interferon), the monoclonal anti-CD20 antibody rituximab, photodynamic therapy and 308-nm excimer laser to mention a few. This review highlights some of the promising new and experimental local therapies for primary CLs and focuses on their efficacy and side effects.

AB - Primary cutaneous lymphomas (CLs) originate in the skin and should be differentiated from secondary skin infiltrates, which are manifestations of lymphomas of nodal or extranodal origin. These rare diseases include various lymphoproliferative disorders: cutaneous T-cell lymphomas, cutaneous B-cell lymphomas and some rare subtypes. As definitive cure is often not possible, it is important to control the disease and alleviate symptoms. Patients with early-stage disease limited to the skin usually require skin-directed therapies using topical agents including corticosteroids, chemotherapeutic drugs, bexarotene gel, electron beam therapy and phototherapy. Each of these are effective; however, all have some disadvantages and are associated with significant adverse events. In the field of skin-directed therapies there are interesting developments using antineoplastic compounds, the retinoid tazarotene, imiquimod, gene therapy products (adenovirus vector expressing γ-interferon), the monoclonal anti-CD20 antibody rituximab, photodynamic therapy and 308-nm excimer laser to mention a few. This review highlights some of the promising new and experimental local therapies for primary CLs and focuses on their efficacy and side effects.

KW - 308-nm excimer laser

KW - Cutaneous lymphoma

KW - Hexadecylphosphocholine

KW - Imiquimod

KW - Methotrexate

KW - Photodynamic therapy

KW - Rituximab

KW - Skin-directed therapy

KW - Tazarotene

KW - TG-1042

UR - http://www.scopus.com/inward/record.url?scp=70349415609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349415609&partnerID=8YFLogxK

U2 - 10.1159/000241302

DO - 10.1159/000241302

M3 - Article

C2 - 19786826

AN - SCOPUS:70349415609

VL - 22

SP - 322

EP - 334

JO - Skin Pharmacology and Physiology

JF - Skin Pharmacology and Physiology

SN - 1660-5527

IS - 6

ER -